Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY2 | Q08462 | 1/20 | 0.35 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20078676 | 0.85 | HPRT1 (0.35) | RIPK1 | |
| SCHEMBL17712309 | 0.84 | TMPRSS2 (0.40) | ADCY2SERPINA3CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL17712307 | 0.84 | TMPRSS2 (0.40) | ADCY2SERPINA3CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL22342700 | 0.84 | TMPRSS2 (0.40) | ADCY2SERPINA3CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL24975950 | 0.83 | CYP3A4 (0.39) | ADCY2SERPINA3CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL18636394 | 0.83 | CYP3A4 (0.39) | ADCY2SERPINA3CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL18667027 | 0.82 | CYP3A4 (0.36) | ADCY2SERPINA3CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL20078687 | 0.80 | SERPINA3 (0.33) | ADCY2SERPINA3RIPK1 | |
| SCHEMBL19223220 | 0.80 | CYP3A4 (0.36) | ADCY2SERPINA3CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL26283274 | 0.79 | POLRMT (0.41) | ADCY2SERPINA3CYP3A4CYP2C9BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |